ABT-199 (venetoclax), a highly selective BCL-2 inhibitor that spares platelets, was then designed and approved by the Food and Drug Administration (FDA) for patients with chronic lymphocytic leukemia (CLL) harboring 17p deletion who have received at least one prior treatment28. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.